Compare TG Therapeutics Inc (TGTX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Vanguard Intermediate Term Corporate Bond ETF trades at $80.48. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VCIT | |
|---|---|---|
Market Cap | $8.36B | — |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $84.82 |
52-Week Low | $26.94 | $80.31 |
Enterprise Value | $8.57B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
VCIT trades at $80.46, down 0.09% on the day, with technical indicators showing a bearish trend from moving averages but bullish momentum from oscillators like the RSI. Recent news highlights institutional buying and favorable comparisons to peers due to its low 0.03% expense ratio and 4.8% yield, positioning it as a cost-effective intermediate-term corporate bond ETF.
The outlook for VCIT is supported by strong income appeal and institutional interest, but risks include interest rate sensitivity and market volatility. Analysts view it positively for its yield and low costs, though the bearish technical trend warrants caution for near-term price movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
